XTL Biopharmaceuticals Ltd (XTLB) - Cash Flow Conversion Efficiency

Latest as of December 2017: -0.083x

Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) has a cash flow conversion efficiency ratio of -0.083x as of December 2017. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-301.00K ≈ $-806.97 USD) by net assets (ILA3.62 Million ≈ $9.70K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XTL Biopharmaceuticals Ltd (XTLB) net asset quality to measure how much of total assets are equity-financed.

XTL Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how XTL Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check XTL Biopharmaceuticals Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

XTL Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ravi Kumar Distilleries Limited NSE:RKDL	0.122x
GreenPower Motor Company Inc NASDAQ:GP	-0.021x
Optima Prima Metal Sinergi JK:OPMS	-0.004x
Sego Resources Inc V:SGZ	-0.015x
Silver Elephant Mining Corp TO:ELEF	0.009x
Nandani Creation Limited NSE:JAIPURKURT	-0.166x
COMTEC SOLAR SYS HD -004 F:8C11	N/A
PAVmed Inc NASDAQ:PAVM	-0.035x

Annual Cash Flow Conversion Efficiency for XTL Biopharmaceuticals Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of XTL Biopharmaceuticals Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see XTLB market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA5.43 Million ≈ $14.57K	ILA-1.62 Million ≈ $-4.34K	-0.298x	+6.52%
2023-12-31	ILA2.22 Million ≈ $5.95K	ILA-707.00K ≈ $-1.90K	-0.318x	-41.35%
2022-12-31	ILA4.00 Million ≈ $10.72K	ILA-901.00K ≈ $-2.42K	-0.225x	-14.54%
2021-12-31	ILA5.33 Million ≈ $14.30K	ILA-1.05 Million ≈ $-2.81K	-0.197x	-44.61%
2020-12-31	ILA6.25 Million ≈ $16.75K	ILA-850.00K ≈ $-2.28K	-0.136x	-4.56%
2019-12-31	ILA6.98 Million ≈ $18.71K	ILA-908.00K ≈ $-2.43K	-0.130x	-32.67%
2018-12-31	ILA8.32 Million ≈ $22.31K	ILA-816.00K ≈ $-2.19K	-0.098x	+68.46%
2017-12-31	ILA3.62 Million ≈ $9.70K	ILA-1.12 Million ≈ $-3.02K	-0.311x	+51.77%
2016-12-31	ILA2.69 Million ≈ $7.20K	ILA-1.73 Million ≈ $-4.64K	-0.645x	-69.27%
2015-12-31	ILA4.89 Million ≈ $13.10K	ILA-1.86 Million ≈ $-4.99K	-0.381x	+27.86%
2014-12-31	ILA4.68 Million ≈ $12.54K	ILA-2.47 Million ≈ $-6.62K	-0.528x	-43.33%
2013-12-31	ILA6.79 Million ≈ $18.19K	ILA-2.50 Million ≈ $-6.70K	-0.368x	--

About XTL Biopharmaceuticals Ltd

TA:XTLB Israel Biotechnology

Market Cap

$4.96 Million

ILA1.85 Billion ILA

Market Cap Rank

#28566 Global

#417 in Israel

Share Price

ILA2.10

Change (1 day)

-4.55%

52-Week Range

ILA1.60 - ILA8.70

All Time High

ILA14.98